RIMKLB

Across TCGA pan-cancer cohorts, RIMKLB RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated RIMKLB data layer compared with 6 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher RIMKLB RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RIMKLB expression acts as an unfavorable survival marker, although some lineages such as CHOL and UCS show a favorable association.

MESO, COAD, and CHOL are the cancer types where RIMKLB RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Quartile	All	0.252	0.497	.003	75	view →
COAD	DFS	Median	All	0.407	0.592	<.001	61	view →
CHOL	DFS	Quartile	All	0.627	0.209	<.001	46	view →
UCS	DFS	Median	III,IV	0.410	0.143	.004	44	view →
UVM	DFS	Median	III,IV	0.267	0.799	.002	38	view →
LIHC	OS	Quartile	II,III,IV	0.763	0.240	.001	32	view →
LUAD	OS	Median	IV	0.338	0.649	.007	30	view →
ACC	DFS	Median	IV	0.155	0.535	.001	25	view →
THYM	DFS	Median	All	0.967	0.657	.005	19	view →
CESC	OS	Tertile	IV	0.635	0.091	.014	18	view →
ESCA	OS	Median	All	1.000	0.659	.020	17	view →
READ	DFS	Median	II,III,IV	0.658	0.915	.012	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

RIMKLB–MESO (OS)

Open the MESO breakdown →